Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen

Byram W. Bridle, Jian Li, Shucui Jiang, Ruby Chang, Brian D. Lichty, Jonathan L. Bramson and Yonghong Wan

*J Immunol* 2010; 184:4269-4275; Prepublished online 17 March 2010; doi: 10.4049/jimmunol.0901447

http://www.jimmunol.org/content/184/8/4269

**References**

This article *cites 46 articles*, 17 of which you can access for free at:

http://www.jimmunol.org/content/184/8/4269.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at:

http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at:

http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at:

http://jimmunol.org/alerts
Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen

Byram W. Bridle,* Jian Li,* Shucui Jiang,† Ruby Chang,† Brian D. Lichty,* Jonathan L. Bramson,* and Yonghong Wan*

Although vaccines targeting tissue differentiation Ags represent a promising strategy for cancer immunotherapy, the risk of triggering autoimmune damage to normal tissues remains to be determined. Immunizing against a melanoma-associated Ag, dopachrome tautomerase (DCT), which normal melanocytes and glial cells also express, allowed concurrent analysis of autoimmune consequences in multiple tissues. We show that vaccination with recombinant adenovirus expressing DCT elicited a strong CTL response in C57BL/6 mice, leading to protection against intracranial challenge with B16-F10 melanoma cells. Both histological analysis and behavioral testing indicated that there was no evidence of neuropathology in vaccinated animals and long-term survivors. Although vitiligo or demyelination could be induced by additional stimuli (i.e., surgery or inflammation) in DCT-vaccinated mice, it did not extend beyond the inflammatory area, suggesting that there is self-regulatory negative feedback in normal tissues. These results demonstrate that it is possible to vaccinate against a tumor embedded in a vital organ that shares the target Ag. *The Journal of Immunology, 2010, 184: 4269–4275.*

Antigen-specific, active immunotherapy offers a promising approach to target both primary and metastatic cancers of various types including intracranial (i.e.,) tumors (1, 2). In this regard, finding Ags exclusively expressed by tumor cells and incorporating them into therapeutic vaccines will not only increase the likelihood of induction of anti-tumor immunity but also reduce the possibility of autoimmune pathology (3). However, development of vaccines directed at tumor-specific Ags is complicated by the fact that each vaccine will likely need to be patient specific (4). As an alternate strategy, efforts have been invested into developing vaccines to target tumor-associated Ags (TAA) that are typically nonmutated proteins overexpressed in specific classes of tumors (5). Indeed, despite the lack of mutation in these proteins, many cancer patients often display spontaneous reactivity to TAA. This realization has led to the development of different strategies that can overcome self-tolerance and elicit an immune response against self-Ags.

Whether pathological damage to normal tissues that express TAA is a requisite outcome of successful anti-tumor immunotherapy remains controversial. Evidence from animal studies has shown that vaccination against melanoma-associated Ags (MAAs), such as tyrosinase-related protein 1 or dopachrome tautomerase (DCT; also known as tyrosinase-related protein 2), is often associated with damage to normal melanocytes, leading to autoimmune vitiligo (6–9). Coupling of anti-tumor immunity and autoimmunity has also been observed in other tumor models, and furthermore, autoimmune symptoms appear to be a positive sign of clinical efficacy in cancer immunotherapy trials (10–13). These results led to the hypothesis that autoimmune destruction is an unavoidable or necessary consequence of effective anti-tumor immunity. However, although the damage to nonessential organs may be acceptable, this hypothesis imposes a conceptual challenge to cancer vaccines targeting Ags that are also expressed by cells in vital organs. We and others have shown that tumor protection can be achieved in the absence of autoimmune disease (14–17). Specifically, we demonstrated in a murine melanoma model that a high-magnitude CTL response induced by recombinant adenovirus (Ad) expressing human DCT (hDCT) did not result in vitiligo unless there was damage (i.e., trauma or inflammation) to the normal tissue (15). A similar observation was made by Lang et al. (18) that large numbers of CTL specific for pancreatic Ag did not necessarily result in autoimmunity diabetes, and overt autoimmune disease occurred only after an inflammatory stimulus that upregulated MHC class I expression in the pancreas. These data identify a concurrent inflammatory event in the target organ as a key factor determining the development of an autoimmune disorder following vaccination against self-tumor Ags.

To directly address the question of whether an effective vaccine imposes a risk to a vital tissue, we extended our melanoma vaccine study from the skin to the brain. Because both melanocytes and CNS tissue differentiate from the neural crest during embryonic development, they share MAAs, including DCT (19–21). This provides an ideal experimental setting to examine the relationship between anti-tumor immunity and autoimmune pathology upon i.c. inoculation with melanoma cells. Furthermore, melanoma commonly metastasizes to the brain in patients (22), and many MAAs are expressed on human malignant gliomas (19, 20, 23); thus, a better understanding of melanoma Ag-based vaccines may have a specific implication in the treatment of brain cancers.

**Materials and Methods**

**Mice and tumor cells**

Age-matched (8–10 wk old at study initiation) female C57BL/6 (H-2b) mice (Charles River Laboratories, Wilmington, MA) were housed in specific pathogen-free conditions. Animal studies complied with Canadian Council on Animal Care guidelines and were approved by McMaster University’s Animal
Research Ethics Board. Murine melanoma (B16-F10) cells were grown in F11 MEM containing 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and vitamin solution, 0.01 mM nonessential amino acids, 50 μM M-2-ME, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Invitrogen, Grand Island, NY).

Recombinant adenovirus. Adenoviral vector construction has been described previously (24). Ad-hDCT expresses the full-length hDCT, and Ad-BHG contains no transgene. Viruses were propagated in 293 cells and purified on a cesium chloride gradient.

Peptides

Immunodominant peptides from DCT that bind to H-2K b [DCT 180–188, SVYDFFVWL; shared by hDCT and mDCT (25)] and I-Ab [hDCT 88–102, KFFHRTCCKTGNA (26)] were synthesized by Biomer Technologies (Hayward, CA).

Vaccination protocol

Anesthetized mice were immunized by i.m. injection of 1 × 10^6 PFU of Ad-hDCT in 100 μl PBS (50 μl/hamstring). Control mice received Ad-BHG or PBS.

Stereotactic surgery

To establish brain tumors or local inflammation, mice received i.e. injections of 1 × 10^8–10^9 B16-F10 cells or 10 μg LPS in 2 μl saline. Mice were placed in a stereotax (Stytax, Don Mills, Ontario, Canada), and under general and local anesthesia, an incision was made in the scalp to expose the skull. A needle mounted on a 10-μl Hamilton syringe (Hamilton, Reno, NV) was positioned over the right hemisphere of the brain, 2.25 mm lateral to Bregma. A small burr hole was drilled through the skull, and the bevel of the needle inserted into the brain parenchyma to a depth of 3 mm. Cells or LPS were injected over a period of 1 min. The needle was left in place for 2 min prior to withdrawal to minimize reflux along the injection tract. The scalp incision was closed with stainless steel clips that were removed 7–10 d later.

Abs

The following mAbs were used in flow cytometry assays: anti-CD16/CD32 (clone 2.4G2) to block FcRs, anti-CD3 (clone 145-2C11), anti-CD4 (clone RM4-5), anti-CD8 (clone 53-6.7) for detecting cell surface markers, and anti–IFN-γ (clone XMG1.2) (all from BD Biosciences, San Diego, CA) for intracellular staining. Immunodepletion studies were conducted with the mAbs GK1.5 (anti-CD4) and/or 2.4G2 (anti-CD8) from American Type Culture Collection (Manassas, VA). Purified mAbs (250 μg in 500 μl saline) were injected i.p. 2 d apart and then twice a week thereafter at a maintenance dose of 200 μg/treatment. The efficiency of specific depletion of lymphocyte subsets was >98% as measured by flow cytometry. For phenotyping skin-infiltrating T cells, the following additional reagents were used: PE-conjugated Kb-SVYDFFVWL tetramer (The Protein Core, Baylor College of Medicine, Houston, TX), recombinant mouse E-selectin/CD62E Fc chimera (R&D Systems, Minneapolis, MN), biotinylated polyclonal Ab to human IgG (Alexis Biochemicals, Plymouth Meeting, PA), PE-Cy7-conjugated streptavidin (BD Biosciences), and anti-CD194/CCR4 (clone 2G12; BioLegend, San Diego, CA).

Detection of DCT-specific T cell responses

Ag-specific T cell responses were quantified by flow cytometric analysis 7 d postvaccination. Blood was collected from the periorbital sinus and RBCs lysed. To study skin-infiltrating T cells, postmortem damaged and normal shaved skin samples measuring 1 × 5 cm were excised from each mouse. Damaged skin had been injected with CFA 48 h prior to harvest or taken from a surgical lesion. Skin was minced, suspended in HBSS containing 0.1% collagenase (Invitrogen), incubated in a shaker at 37 °C at 200 rpm for 45 min, and then pressed through a nylon mesh filter with a 40-μm pore size to obtain a single-cell suspension. Mononuclear cells were stimulated with peptides (1 μg/ml DCT 101–110 and 20 μg/ml HDC 101–110) in the presence of brefeldin A (GolgiPlug; BD Pharmingen; San Diego, CA), 1 μg/ml added after 2 h of incubation. After 6 h, total incubation time cells were treated with anti-CD16/CD32 and surface markers fluorescently labeled by addition of Abs. Cells were then permeabilized and fixed with Cytofix/Cytoperm (BD Pharmingen) and stained for intracellular cytokines. Data were acquired using a FACSAria flow cytometer with FACSDiva 5.0.2 software (BD Pharmingen) and analyzed with FlowJo Mac Version 6.3.4 software (Tree Star, Ashland, OR).

Histological analyses

Brains were fixed for 3 d in 10% formalin, transferred to 70% ethanol, paraffin-embedded, sectioned at a thickness of 10 μm, and stained with H&E (Sigma-Aldrich Canada, Oakville, Ontario, Canada). To stain myelin, sections (10–25 μm thick) were dehydrated in graded alcohol and placed in 0.1% Luxol fast blue at 37 °C overnight. Sections were then differentiated in 0.05% LiCO3 for 4 min and then dehydrated in graded alcohol and xylene (all reagents from Sigma-Aldrich, St. Louis, MO). For CD8 detection, brains frozen in optimal cutting temperature medium were sectioned at a thickness of 10 μm, fixed with acetone, treated with peroxidase, stained with rat anti-mouse CD8 (clone 53-6.7; BD Biosciences) rat on mouse HRP polymer kit (Biocare Medical, Concord, CA), and resolved using a 3-amino-9-ethylcarbazole substrate kit (In-vitrogen). Myelin was quantified by measuring integrated density of Luxol fast blue in stained sections taken through the injection site using ImageJ software (version 1.42q, http://rsb.info.nih.gov/ij/; W. Rasband, National Institutes of Health, Bethesda, MD) (27).

Vitiligo assessment

Mice were immunized with Ad-hDCT, and 1 d later, their skins were “painted” with 120 μl 2,4-dinitro-1-fluorobenzene (DNFB, 0.2% diluted in acetone/olive oil at a 4:1 ratio) (Sigma-Aldrich). Vitiligo development was monitored weekly for 8 wk after the DNFB challenge.

Behavioral assessments

To further evaluate the long-term effect of vaccination therapy on brain functions, a set of preliminary behavioral assessments were performed in mice that survived >90 d posttherapy and age-matched unvaccinated mice, as described previously (28). Briefly, each individual mouse was placed in an empty cage where object avoidance, olfactory, auditory, and visual cliff tests were conducted. Neurological reflexes including balance, eye blink, ear twitch, whisker orientation, and righting were assessed (29, 30). Upon completion of all tests for all animals within the same cage, behavior, such as locomotion, interaction with littermate, and grooming, were noted (31). A general health assessment consisting of body weight, body temperature, and fur condition were also recorded at the end of the test session.

Statistical analyses

GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA) was used to graph data and for statistical analyses. If required, data were normalized by log transformation. T cell responses were analyzed by Student two-tailed t test, one- or two-way ANOVA. Differences between means were considered significant at p < 0.05. Means plus SE bars are shown. Survival data were analyzed using the Kaplan-Meier method and the log-rank test.

Results

Ad-hDCT immunization induced effective protection against i.c. challenge with B16-F10 cells

Murine melanoma B16-F10 cells are known for their aggressiveness and we have previously demonstrated that immunization with Ad-hDCT provides robust protection against s.c. and challenge with these
cells (15, 32). We found that i.c. injection of 1 × 10^3 B16-F10 cells resulted in formation of lethal tumors within only 13 d of injection (Fig. 1A, left panel). However, immunization with Ad-hDCT 7 d prior to challenge effectively prevented tumor growth (Fig. 1A, right panel), demonstrating the potency of Ad-hDCT as a potential vaccine for brain cancers that express DCT. This efficacy observed at early time points translated into a significant extension of survival (Fig. 1B). Mice treated with PBS (data not shown) or a control Ad vector (Ad-BHG) had a median survival of 15 d posttumor challenge, whereas immunization with Ad-hDCT resulted in a significant survival benefit in all treated mice (median = 64 d; p < 0.0001). More importantly, 27% (6 of 22) of vaccinated mice completely rejected implanted tumor cells, offering a unique model for the subsequent analysis of the acute and chronic impact of vaccine-induced autoimmunity in a vital organ.

Protection against i.c. B16-F10 tumors depended on CD8+ T cells

To evaluate the induction of Ag-specific T cells by Ad-hDCT, we determined the frequency of both CD8+ and CD4+ T cells that were capable of producing IFN-γ in response to restimulation with their corresponding peptides. At 8 d postvaccination, >3% of blood-derived CD8+ T cells were producing IFN-γ in response to the immunodominant epitope DCT_180-188, shared between mice and humans (Fig. 2A). A significant level of CD4+ T cells (0.4%) specific for hDCT_88-102, a recently identified helper peptide (26), was also evident by IFN-γ production (Fig. 2B). To determine their relative contribution to tumor protection, immunized mice were depleted of CD4+ and/or CD8+ T cells 2 d before i.c. challenge. Protection was completely abrogated by depletion of CD8+ but not CD4+ T cells, indicating that CD8+ T cells were the primary effectors for i.c. tumor rejection (Fig. 2C). This notion is further supported by histological staining that revealed more immune infiltrates at the tumor challenge site in DCT-vaccinated animals compared with controls (Fig. 2D, upper panels), and many of these infiltrates were CD8+ T cells (Fig. 2D, lower panels).

No evidence of acute neuropathology despite autoimmune targeting of DCT

For evaluation of potential acute autoimmune or bystander damage, mice were immunized with Ad-hDCT and challenged i.c. 7 d later with a high dose of 1 × 10^5 B16-F10 cells to ensure survival of tumor cells so malignant lesions could be identified. Rapid dissemination of the melanoma to the ventral surface and brain stem was observed in only 4 d (Fig. 3A, left panel). However, immunization with Ad-hDCT 7 d prior to challenge prevented tumor dissemination (Fig. 3A, right panel), confirming the potency of Ad-hDCT. Four days after the high-
dose challenge, mice were euthanized, their brains harvested, and frozen sections were stained (Fig. 3B) with H&E (left panels) or Luxol fast blue to detect myelin (right panels). A normal brain from an age-matched mouse was included. Again, the potency of Ad-hDCT immunization on inhibition of tumor growth within the brain parenchyma was evident relative to sham-treated controls (Fig. 3B, left middle and left lower panels; see circles). This acute phase of DCT-specific cytotoxicity in the brain did not trigger any obvious damage to normal tissues. Although swelling of tumor-adjacent brain tissues could be observed in some untreated mice (example in Fig. 3A, left middle panel with high-magnification inset), their neurons and myelin sheaths remained intact (Fig. 3A, right middle panel with high-magnification inset).

**Immunization with Ad-hDCT caused autoimmune pathology in inflamed normal tissues**

We previously reported that i.m. immunization with Ad-hDCT did not cause melanocyte damage (vitiligo) unless there was trauma/inflammation within the skin (15). Consistent with this earlier observation, all Ad-hDCT–immunized mice in the current model developed severe vitiligo along the scalp incision site, whereas this lesion was absent in all sham-treated mice (Fig. 4A). Depletion of CD8+ T cells before the surgery completely abrogated vitiligo induction, whereas CD4 depletion had a significant but incomplete effect, suggesting that CD8+ T cells are the primary effectors in this autoimmune destruction (Fig. 4B). Tetramer staining indicated that a substantial number of DCT-specific CD8+ T cells were indeed recruited into damaged skin and 50.4% (± SE of 3.5; n = 3) of these expressed E-selectin ligand and/or CCR4 (Fig. 4C), a surface phenotype consistent with skin-homing T cells (33). Interestingly, in all cases, the vitiligo was limited to the area immediately surrounding the incision. To further delineate the relationship between skin damage and vaccine-induced vitiligo, a hapten DNFB was used to induce skin sensitization in a controlled fashion. As shown in Fig. 4D, DNFB alone did not damage melanocytes (top panel), whereas the size of the vitiligo lesion directly correlated with the extent of the DNFB-induced skin inflammation in Ad-hDCT–immunized mice (bottom panel). The results reinforce the idea that the number of autoreactive T cells did not limit the extent of vitiligo, but their access to normal skin was apparently controlled by the degree of local inflammation.

To determine whether additional inflammatory stimulation causes autoimmune pathology in the brain, LPS was injected i.c. 14 d after treatment with Ad-hDCT or PBS. Compared with sham injection, LPS elicited more obvious inflammation, although it was limited to the injection site (Fig. 5, upper panels) and resolved in 3 d (data not shown). Considerably more CD8+ T cells were evident in Ad-hDCT–vaccinated mice (Fig. 5, middle panels), which correlated with localized demyelination (Fig. 5, lower panels; mean integrated density of Luxol fast blue stain = 2.7 ± 1.4 SE, n = 5 for Ad-hDCT + LPS versus 10.2 ± 2.6, n = 5 for PBS + LPS; p = 0.027). Sham injection or LPS challenge alone was insufficient to induce tissue damage (Fig. 5, lower panels). These observations confirm the concomitant requirement of both Ag-specific autoimmunity and local tissue inflammation for the induction of autoimmune sequelae.
Ad-hDCT vaccination provided a potent therapeutic effect

We next extended the analysis to evaluate the therapeutic potential of Ad-hDCT in mice bearing pre-existing tumors in the brain. In this regard, mice were injected i.c. with $1 \times 10^5$ B16-F10 cells and then treated with Ad-hDCT 5 d later. Eleven days after treatment, the whole brains were harvested from both naive (tumor-free) and treated (tumor-bearing) mice for quantitative analysis of efficacy. Tumor burden was determined by subtracting the mean weight of tumor-free brains from those in the tumor-bearing groups. Fig. 6A shows that the mean tumor weight in Ad-hDCT-immunized mice was 4.7-fold less than that in mice treated with a control Ad vector (47.1 ± 21.3 versus 9.9 ± 2.8 mg; $p < 0.05$). Furthermore, mice treated 5 d postgraftament had a significantly longer median survival time following Ad-hDCT treatment, compared with sham-treated controls (Fig. 6B). An additional study extended this observation of Ad-hDCT–mediated therapeutic efficacy by demonstrating that immunization of mice with 7-d-old brain tumors increased median survival to 27 d versus only 15 for sham-treated controls ($p = 0.0067$) (Fig. 6C). As had been observed in the prophylactic challenge model, vitiligo was evident in all mice treated in the therapeutic setting (Fig. 6D). However, these lesions were less severe than those observed in the prophylactic model (Fig. 4A), presumably due to altered intervals between the peak of the anti-self-immune response (10–14 d after immunization) and surgery-induced skin damage (1–2 d after surgery). Specifically, immunization was carried out several days after tumor inoculation, such that a significant amount of wound healing had occurred by the time the CTL response was fully activated.

Discussion

Strategies to eliminate cancer cells by breaking tolerance to self-Ags have raised an issue regarding the potential risk for collateral auto-immune damage to normal tissues (34–36). Using a murine melanoma model, we and others have demonstrated that the development of effective anti-tumor immunity indeed results in autoimmune vitiligo, especially when there is a concurrent inflammatory event in healthy tissues that express Ags carried by the vaccine (8, 15, 37, 38). Results from several clinical trials also indicate that development of these survivors, despite immunization with Ad-hDCT and tumor destruction in the brain (data not shown). Because DCT-immunized mice challenged with LPS had evidence of acute demyelination at the injection site, we repeated the study to determine whether there were any signs of chronic damage. At 90 d post-LPS challenge, these mice passed all behavioral tests (Table I) and did not have any demyelination (mean integrated density of Luxol fast blue stain = 241.1 ± 1.0 SE, $n = 5$ for naive controls versus 240.2 ± 1.9, $n = 5$ for LPS challenge).

Table I. Mice protected from i.c. melanoma exhibit normal behavior

<table>
<thead>
<tr>
<th>Physical Evaluation</th>
<th>Neurological Reflex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>Object Avoidance</td>
</tr>
<tr>
<td>Rejected tumors</td>
<td>2/21</td>
</tr>
<tr>
<td>Naive</td>
<td>27/27</td>
</tr>
<tr>
<td>Ad-hDCT + LPS</td>
<td>5/5</td>
</tr>
</tbody>
</table>

Mice vaccinated with Ad-hDCT were challenged i.c. with B16-F10 cells or LPS 7–14 d later. Some mice completely rejected the implanted tumor cells. Twenty-one long-term survivors of the tumor challenge (>90-d survival), 5 mice at 90 d post-LPS challenge, and 27 age-matched naive controls were enrolled in a series of behavior studies designed to assess general health and neurophysiological functions. Absence of brain tumors in these mice was confirmed by postmortem gross and histological examination following testing.

*Means (± SEM) were not significantly different.
†The mouse that failed these tests was the longest-term survivor and severely overweight.
‡The whiskers on two of these mice were absent because of barbering.
autoimmune toxicities correlated with tumor regression (13, 39–41). These observations point to the possibility that autoimmune pathologies may be an unavoidable or even favorable outcome of cancer immunotherapies.

However, because the potential destruction of normal brain tissue could have severe consequences, the balance between anti-tumor immunity and autoimmune pathology in the case of cerebral malignancies needed to be investigated. The tumor model and vaccination approach presented in this study provided several unique features to address this issue. First, the potency of the Ad-hDCT vaccine allowed us to achieve treatment efficacy against i.c. growth of B16-F10 melanomas and provided an opportunity to analyze pathological consequences both in early stages and in long-term survivors. Second, the potential autoimmune destruction could be concomitantly evaluated in the skin and brain, both of which express the target Ag. Third, i.c. challenge with B16-F10 cells did not only provide a brain tumor model but also served as a local inflammatory stimulus within the brain.

We previously reported that vitiligo lesions following melanoma immunotherapy required two events: Ag-specific immunity plus damage to the skin (15). The current study corroborates this. Specifically, vitiligo was associated with the scalpel incision site in Ad-hDCT–immunized mice. Moreover, vitiligo was severe in the prophylactic model where immune responses were peaking at the time of injury to the skin. In contrast, vitiligo severity was reduced in the therapeutic model where >1 wk of wound healing occurred before significant DCT-specific T cell responses were detectable. These observations reinforce our hypothesis that autoimmune pathology following effective cancer vaccination is the result of secondary trauma to normal tissues, and its severity is affected by the degree and persistence of normal tissue damage. We speculate that tissue inflammation/trauma is required to recruit autoreactive T cells, as demonstrated in Fig. 4C, and to modulate expression of MHC molecules and target Ags. Our results are consistent with the finding by Lang et al. (18) that highly activated CD8+ T cells could coexist with pancreatic β islet cells expressing the relevant autoantigen; however, overt autoimmune disease occurred when an inflammatory response was coupled.

Despite the presence of robust DCT-specific CD8+ T cells and the evidence that DCT is expressed in normal brain (19–21, 23, 42), we never saw any neuropathology in Ad-hDCT–immunized mice. This may be explained by the inherent immune-privileged nature of the brain (43) or the lack of inflammatory signals to recruit autoreactive T cells into sites distal to the i.c. tumors. Our results confirm that Ag-specific vaccines are capable of inducing an anti-tumor response within the immunologically privileged brain and that the CNS is accessible to systemic immunotherapy (44). More importantly, similar to what we observed in skin, immune destruction appeared to only focus on the inflammatory area (i.e., tumor) and did not extend beyond the site of tumor growth. Furthermore, the lack of behavioral anomalies or demyelination in normal brain tissue by long-term survivors provides further evidence that cerebral cancer can be eliminated by autoreactive T cells while leaving the CNS unharmed. The linkage between tissue inflammation and autoimmune pathology is further supported by deliberate i.c. injection of LPS where only Ad-hDCT–immunized animals exhibit localized, acute demyelination, presumably due to the recruitment of CD8+ T cells that recognize DCT expressed by normal glial cells. The fact that demyelination was no longer evident at 90 d post-LPS challenge suggests the cells that were acutely destroyed could be renewed following cessation of inflammatory stimulation. Taken together, these results clearly demonstrate that the inflammation is tightly regulated in normal tissues, which limits the initiation and progression of autoimmune destruction in the vaccinated host.

It is possible that additional stringent mechanisms may also be operational in the brain to regulate local immune responses to avoid autoimmune pathology. For instance, although most tumors are inherently inflammatory and the integrity of the blood-brain barrier is locally compromised allowing extravasation of activated T cells, their trafficking may be more limited in normal parenchyma (45). However, it remains to be determined whether the local environment functionally influences brain-infiltrating lymphocytes. The fact that demyelination was no longer evident at 90 d post-LPS challenge suggests the cells that were acutely destroyed could be renewed following cessation of inflammatory stimulation. Taken together, these results clearly demonstrate that the inflammation is tightly regulated in normal tissues, which limits the initiation and progression of autoimmune destruction in the vaccinated host.

Overall, our findings provide proof-of-principle that self-Ags can safely be targeted by cancer immunotherapy, even if the tumor is embedded within a vital tissue sharing the same Ag. Compelling evidence supports the concept that anti-tumor immunity will only spill over into autoimmune pathology if linked by inflammation. Given the demonstration of MAA expression by gliomas, our findings on vaccination efficacy and the relationship between anti-tumor immunity and autoimmune pathology have significant implications for the design of therapies directed not only against brain melanoma but also potentially for primary brain cancers.

Acknowledgments
We thank Duncan Chong, Xueya Feng, Ying Chuyan, Mary-Jo Smith, Mary Bruni, Cai Jiang, and Jie Huang for technical assistance and Dr. Zhou Xing for helping with histological examination.

Disclosures
The authors have no financial conflicts of interest.
References


11. Ram, M., and Y. Shoenfeld. 2007. Harnessing autoimmunity (vitiligo) to treat mel-

12. Ram, M., and Y. Shoenfeld. 2007. Harnessing autoimmunity (vitiligo) to treat mel-


15. Lane, C., J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan. 2004. CTL-depen-

16. Bronte, V., E. Apolloni, R. Ronca, P. Zamboni, W. W. Overwijk, D. R. Surman,


22. Bronte, V., E. Apolloni, R. Ronca, P. Zamboni, W. W. Overwijk, D. R. Surman,


24. Yang, T. C., J. Millar, T. Groves, N. Grinstein, R. Parsons, S. Takenaka, Y. Wan,

25. Sanz, M., K. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and

26. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwan-


29. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwan-


31. Parkhurst, M. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and


34. Malyankar, U. M. 2007. Tumor-associated antigens and biomarkers in cancer and

35. Malyankar, U. M. 2007. Tumor-associated antigens and biomarkers in cancer and


37. Sanz, M., K. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and

38. Sanz, M., K. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and

39. Sanz, M., K. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and

40. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwan-

41. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwan-

42. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwan-

43. Mrass, P., and W. Weninger. 2006. Immune cell migration as a means to control

44. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet,

45. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet,

46. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet,

47. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet,

48. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet,

49. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet,

50. Walker, P. R., T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet,